RIO DE JANEIRO, BRAZIL - The Brazilian Health Regulatory Agency (ANVISA) has for the first time approved a product used in a specific type of therapy for blood-related cancers (hematological), such as leukemia, lymphoma and myeloma.
The product is designed for people up to 25 years of age with certain types of Acute Lymphoblastic Leukemia, as well as for adult patients with specific types of Lymphoma.
According to ANVISA, this is a pioneering treatment. The agency's technical team concluded that the product meets the minimum requirements in terms of safety and efficacy.
Novartis' Kymriah can be employed in the . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here